Group 1 - The core viewpoint of the news is that Lai Mei Pharmaceutical experienced a decline in stock price and trading volume, with significant net financing outflows on September 17, indicating potential investor concerns [1] - On September 17, Lai Mei Pharmaceutical's stock fell by 1.93%, with a trading volume of 107 million yuan. The net financing buy was -6.93 million yuan, with a total financing and securities balance of 202 million yuan [1] - The financing balance of Lai Mei Pharmaceutical is 202 million yuan, accounting for 4.18% of its market capitalization, which is above the 70th percentile level over the past year, indicating a high level of financing activity [1] Group 2 - As of September 10, the number of shareholders of Lai Mei Pharmaceutical decreased to 35,500, a reduction of 2.42%, while the average circulating shares per person increased by 2.48% to 29,746 shares [2] - For the first half of 2025, Lai Mei Pharmaceutical reported a revenue of 377 million yuan, a year-on-year decrease of 1.19%, and a net profit attributable to the parent company of -31.38 million yuan, a significant year-on-year decline of 2462.45% [2] - Since its A-share listing, Lai Mei Pharmaceutical has distributed a total of 280 million yuan in dividends, with no dividends paid in the last three years [3]

Core Insights - Zhongheng Group announced the approval of two drugs by the National Medical Products Administration, indicating a positive development for the company's product portfolio [2] Drug Approval Details - The approved drugs include Nicardipine Tablets (specification: 5mg) and Ketorolac Tromethamine Injection (specification: 1ml: 30mg) [2]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (30mg per 1ml) [2] Group 1 - The company announced the receipt of drug registration certificates for Nicardipine Tablets and Ketorolac Tromethamine Injection [2]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]

Company Overview - Recently, Laimei Pharmaceutical (SZ 300006, closing price: 4.58 yuan) announced the approval of two drug registration certificates by the National Medical Products Administration for Nicorandil tablets and Ketorolac Tromethamine injection [1] Financial Performance - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] Market Position - As of the report, Laimei Pharmaceutical has a market capitalization of 4.8 billion yuan [1]

Core Viewpoint - Lai Mei Pharmaceutical has received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml: 30mg) [1] Group 1: Drug Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (30mg/1ml) [1] Group 1 - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

证券代码：300006 证券简称：莱美药业 公告编号：2025-046 重庆莱美药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 | 药品名称 | 药品通用名称：酮咯酸氨丁三醇注射液 | | --- | --- | | | 英文名/拉丁名：Ketorolac Trometamol Injection | | 主要成份 | 酮咯酸氨丁三醇 | | 剂型 | 注射剂 | | 规格 | 1ml:30mg | | 证书编号 | 2025S02756 | | 药品注册标准编号 | YBH20742025 | | 包装规格 | 10 支/盒 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 3 类 | | 药品批准文号 | 国药准字 H20255358 | | 药品有效期 | 个月 24 | | 处方药/非处方药 | 处方药 | | 上市许可持有人 | 名称：重庆莱美药业股份有限公司 | | | 地址：重庆市南岸区玉马路 号 99 | | 生产企业 | 名称：重庆莱美药业股份有限公司 | | | 地址：重庆市 ...

Core Viewpoint - The company, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (30mg/1ml) [1] Group 1: Drug Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain [1]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for two drugs: Nicorandil tablets (5 mg) and Ketorolac Tromethamine injection (30 mg per 1 ml) [1] Group 1: Product Approvals - Nicorandil tablets are indicated for the treatment of angina pectoris [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1]